|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00133445 |
The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same combination vaccine at 2, 4, and 6 months of age. Additionally, researchers will assess the body's antibody response (proteins produced by the body's immune system that help fight infections) following each vaccine dose. The study will enroll 5 healthy newborns, ages 0-5 days. Participants will be involved in study related procedures for up to 280 days, including blood sample collection and 5 study visits.
Condition | Intervention | Phase |
Diphtheria Hepatitis B Pertussis Tetanus Poliomyelitis |
Biological: DTaP-Hep B-IPV Vaccine Biological: Monovalent Hep B Vaccine Drug: Placebo |
Phase II |
MedlinePlus related topics: | Diphtheria Hepatitis Hepatitis B Polio and Post-Polio Syndrome Tetanus Whooping Cough |
Drug Information available for: | Hepatitis B Vaccines Sodium chloride Aluminum hydroxide Algeldrate Aluminum |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Single Blind (Caregiver), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized, Single Blinded Study of the Safety and Immunogenicity of Pentavalent DTaP-Hep B-IPV Combination Vaccine (Pediarix™; GlaxoSmithKline (GSK) Biologicals) Administered to Healthy Neonates and Infants at Birth, 2, and 6 Months of Age Compared to a Routine Infant Schedule at 2, 4, and 6 Months of Age |
Enrollment: | 5 |
Study Start Date: | December 2005 |
Study Completion Date: | August 2006 |
Primary Completion Date: | August 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
A: Experimental
Group A will receive DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, 2 and 6 months of age.
|
Biological: DTaP-Hep B-IPV Vaccine
U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
Biological: Monovalent Hep B Vaccine
U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
Drug: Placebo
Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
|
B: Active Comparator
Group B will receive the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at 2, 4 and 6 months of age.
|
Biological: Monovalent Hep B Vaccine
U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
|
Routine immunization at birth is standard for hepatitis B in the U.S. and for BCG in many countries. Other vaccines have not been routinely administered at birth largely due to concerns relating to immaturity of the neonatal immune system and the possibility of reduced immune response to vaccine antigens. With the recent licensure in the US of a pentavalent combination vaccine (DTaP-Hep B-IPV; Pediarix™; GlaxoSmithKline Biologicals) researchers propose to evaluate a new immunization schedule that includes a birth dose of this vaccine, in an effort to determine adequacy of neonatal immune response to the study vaccine antigens. The primary objectives of this study are: to evaluate the safety of administering the pentavalent combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, two and six months of age compared to the administration of a HepB vaccine (Engerix-B) at birth and the same pentavalent combination vaccine at two, four and six months of age; and to assess age specific antibody response following each vaccine dose. The study enrolled 5 healthy newborns; 0 to 5 days of age, greater than or equal to 37 weeks gestation, and greater than 2500 gm birth weight were recruited from two Southern California Kaiser Permanente medical centers. Infants were randomized to one of 2 study groups: Group A received DTaP-HepB-IPV (Pediarix™) vaccine along with other required vaccines at birth, two, six months of age; Group B will received the monovalent HepB vaccine (Engerix-B) at birth, the DTaP-HepB-IPV (Pediarix™) vaccine with other vaccines at two, four and six months. Children will be evaluated for post-vaccination adverse events. Blood will be collected and immunogenicity evaluated by standardized humoral immunologic assays. The main outcome measures are to assess immune responses to each vaccine antigen over time, antibodies to pertussis (PT, FHA, PRN), diphtheria, tetanus, Hib, polio (Types 1, 2, 3) and hepatitis B (HbsAg) will be evaluated. The secondary outcome measures are to assess vaccine safety, systemic and local immediate reactions.
Ages Eligible for Study: | up to 5 Days |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Prenatal Inclusion Criteria
Birth Inclusion Criteria
Exclusion Criteria:
Prenatal Exclusion Criteria
Birth Exclusion Criteria
Responsible Party: | HHS/NIAID/DMID ( Robert Johnson ) |
Study ID Numbers: | 03-062 |
First Received: | August 19, 2005 |
Last Updated: | October 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00133445 |
Health Authority: | United States: Federal Government; United States: Food and Drug Administration; United States: Institutional Review Board |
|
|
|
|
|